KROS Q3 2022 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$28M

Net Income

-$24M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$253M

Total Liabilities

$12M

Stockholders' Equity

$241M

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$28M	-$20M	-38.5%
Net Income	-$24M	-$20M	-15.8%

Revenue Segments

License

$144M100%